SCHEMBL10294170

SCHEMBL10294170

CCS(=O)(=O)Nc1cccc(N(C)C(C)(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.44
BRD4 O60885 3/20 0.44
BRDT Q58F21 1/20 0.43
ALDH1A1 P00352 4/20 0.43
NR3C1 P04150 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
ADRA2A P08913 1/20 0.41
ADRA1A P35348 1/20 0.41
KIF11 P52732 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 2/20 0.40
HSP90AA1 P07900 1/20 0.40
THRB P10828 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10294704 0.81 ALDH1A1 (0.44) BRD4BRDTALDH1A1NR3C1SMN1; SMN2
SCHEMBL8713187 0.80 NR3C1 (0.52) BRD4BRDTALDH1A1NR3C1SMN1; SMN2
SCHEMBL10294177 0.79 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2LMNAHTTKMT2A
SCHEMBL10589236 0.79 NR3C1 (0.41) NR3C2BRD4BRDTALDH1A1NR3C1
SCHEMBL10294172 0.76 NR3C2 (0.50) NR3C2BRD4BRDTSMN1; SMN2LMNA
SCHEMBL10294094 0.75 POLB (0.56) ALDH1A1SMN1; SMN2LMNAHTTRAB9A
SCHEMBL8274370 0.74 NR3C2 (0.57) NR3C2BRD4BRDTSMN1; SMN2LMNA
SCHEMBL10294096 0.72 ALDH1A1 (0.57) ALDH1A1HPGDMAPT
SCHEMBL20782198 0.72 ADRA2A (0.52) NR3C2BRD4BRDTSMN1; SMN2LMNA
SCHEMBL18649047 0.72 NR3C2 (0.54) NR3C2BRD4BRDTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172361-A1 TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172361-A1 TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CYP3A5, CYP11B2, ABCB1 NR3C2 55/4885BRD4 1262/4885BRDT 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.